What is the typical dosing regimen for polymyxin B and colistin (polymyxin E) in patients with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Polymyxin B and Colistin Dosing in Patients with Normal Renal Function

For patients with normal renal function, polymyxin B should be dosed at 1.5-3 mg/kg/day divided into 2 doses with a loading dose of 2-2.5 mg/kg, while colistin (polymyxin E) should be administered with a loading dose of 6-9 million IU followed by 4.5 million IU every 12 hours. 1, 2, 3

Polymyxin B Dosing

Standard Dosing

  • Loading dose: 2-2.5 mg/kg 1
  • Maintenance dose: 1.5-3 mg/kg/day divided into 2 doses 1
  • FDA labeling recommends 15,000 to 25,000 units/kg/day for adults with normal renal function 3
    • Note: 1 mg of polymyxin B = 10,000 units

Administration

  • Can be administered as continuous infusion 1
  • Intravenous administration is preferred over intramuscular due to severe pain at injection sites 3
  • Dosing should be based on actual body weight, though some guidelines suggest using ideal body weight for obese patients 2

Colistin (Polymyxin E) Dosing

Standard Dosing

  • Loading dose: 6-9 million IU (equivalent to 5 mg/kg colistin base activity) 1, 2
    • Loading dose should be administered to all patients regardless of renal function
  • Maintenance dose: 9 million IU/day divided into 2-3 doses 1
    • Typically administered as 4.5 million IU every 12 hours 2
  • FDA labeling recommends 2.5-5 mg/kg/day of colistin base activity divided into 2-4 doses 4

Administration

  • Administered as colistimethate sodium (CMS), which is the inactive prodrug of colistin
  • Extended interval dosing (4.5 million IU every 12 hours) is recommended for critically ill patients 2
  • Important conversion: 1 million IU of colistin is equivalent to approximately 80 mg of CMS or 30 mg of colistin base activity 1, 2

Clinical Considerations

Pharmacokinetic Considerations

  • Polymyxin B clearance is not significantly affected by renal function, with recent studies showing comparable drug exposure in patients with normal and impaired renal function 5, 6
  • Colistin requires a loading dose because plasma concentrations may be suboptimal for 2-3 days before reaching steady state 1
  • Polymyxin B may be preferred over colistin in patients with renal impairment as it doesn't require dosage adjustments based on renal function 1, 6

Monitoring

  • Close monitoring of renal function is essential during therapy with both agents, as 14-20% of patients may develop acute kidney injury 2
  • Therapeutic drug monitoring may be beneficial but is not widely available

Common Pitfalls

  1. Inconsistent dosing units: Colistin may be prescribed in different units (IU vs. mg), which can lead to dosing errors 2
  2. Inadequate loading doses: Failure to administer loading doses can result in suboptimal plasma concentrations for several days 1
  3. Inappropriate renal dose adjustments for polymyxin B: Unlike colistin, polymyxin B dosing should not be adjusted based on renal function 6

Indications and Duration

  • Reserved for infections caused by multidrug-resistant gram-negative bacteria
  • Treatment duration depends on infection site:
    • Complicated urinary tract infections: 5-10 days
    • Complicated intra-abdominal infections: 5-10 days
    • Ventilator-associated or hospital-acquired pneumonia: 10-14 days
    • Bacteremia: 10-14 days 2

Both polymyxin B and colistin are critical last-line antibiotics for multidrug-resistant gram-negative infections, and their use should be guided by antimicrobial susceptibility testing and, when possible, infectious disease consultation.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colistin Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.